178 related articles for article (PubMed ID: 35105904)
1. Ovarian toxicity of carboplatin and paclitaxel in mouse carriers of mutation in BRIP1 tumor suppressor gene.
Ntemou E; Vidal PD; Alexandri C; Van den Steen G; Lambertini M; Demeestere I
Sci Rep; 2022 Feb; 12(1):1658. PubMed ID: 35105904
[TBL] [Abstract][Full Text] [Related]
2. Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency.
Oktay KH; Bedoschi G; Goldfarb SB; Taylan E; Titus S; Palomaki GE; Cigler T; Robson M; Dickler MN
Fertil Steril; 2020 Jun; 113(6):1251-1260.e1. PubMed ID: 32331767
[TBL] [Abstract][Full Text] [Related]
3. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
4. BRCA-related ATM-mediated DNA double-strand break repair and ovarian aging.
Turan V; Oktay K
Hum Reprod Update; 2020 Jan; 26(1):43-57. PubMed ID: 31822904
[TBL] [Abstract][Full Text] [Related]
5. Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
Alter BP; Best AF
Breast Cancer Res Treat; 2020 Jul; 182(2):465-476. PubMed ID: 32488392
[TBL] [Abstract][Full Text] [Related]
6. Rare
Moyer CL; Ivanovich J; Gillespie JL; Doberstein R; Radke MR; Richardson ME; Kaufmann SH; Swisher EM; Goodfellow PJ
Cancer Res; 2020 Feb; 80(4):857-867. PubMed ID: 31822495
[TBL] [Abstract][Full Text] [Related]
7. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
[TBL] [Abstract][Full Text] [Related]
8. Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer.
Park JS; Lee ST; Nam EJ; Han JW; Lee JY; Kim J; Kim TI; Park HS
BMC Cancer; 2018 Jan; 18(1):83. PubMed ID: 29338689
[TBL] [Abstract][Full Text] [Related]
9. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
[TBL] [Abstract][Full Text] [Related]
10. Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2009 May; 115(1):51-5. PubMed ID: 18483852
[TBL] [Abstract][Full Text] [Related]
11. Retesting of women who are negative for a
Lerner-Ellis J; Sopik V; Wong A; Lázaro C; Narod SA; Charames GS
J Med Genet; 2020 Jun; 57(6):380-384. PubMed ID: 31784482
[TBL] [Abstract][Full Text] [Related]
12. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer.
Ryu JS; Lee HY; Cho EH; Yoon KA; Kim MK; Joo J; Lee ES; Kang HS; Lee S; Lee DO; Lim MC; Kong SY
Cancer Sci; 2020 Oct; 111(10):3912-3925. PubMed ID: 32761968
[TBL] [Abstract][Full Text] [Related]
13. Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers.
Rebbeck TR; Mitra N; Domchek SM; Wan F; Chuai S; Friebel TM; Panossian S; Spurdle A; Chenevix-Trench G; ; Singer CF; Pfeiler G; Neuhausen SL; Lynch HT; Garber JE; Weitzel JN; Isaacs C; Couch F; Narod SA; Rubinstein WS; Tomlinson GE; Ganz PA; Olopade OI; Tung N; Blum JL; Greenberg R; Nathanson KL; Daly MB
Cancer Res; 2009 Jul; 69(14):5801-10. PubMed ID: 19584272
[TBL] [Abstract][Full Text] [Related]
14. Do BRCA1 and BRCA2 gene mutation carriers have a reduced ovarian reserve? Protocol for a prospective observational study.
Winship AL; Willson C; Hansen KR; Hutt KJ; Hickey M
BMJ Open; 2019 Nov; 9(11):e033810. PubMed ID: 31772111
[TBL] [Abstract][Full Text] [Related]
15. The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation.
Winship AL; Griffiths M; Lliberos Requesens C; Sarma U; Phillips KA; Hutt KJ
Hum Reprod; 2020 Aug; 35(8):1864-1874. PubMed ID: 32604417
[TBL] [Abstract][Full Text] [Related]
16. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer.
Weber-Lassalle N; Hauke J; Ramser J; Richters L; Groß E; Blümcke B; Gehrig A; Kahlert AK; Müller CR; Hackmann K; Honisch E; Weber-Lassalle K; Niederacher D; Borde J; Thiele H; Ernst C; Altmüller J; Neidhardt G; Nürnberg P; Klaschik K; Schroeder C; Platzer K; Volk AE; Wang-Gohrke S; Just W; Auber B; Kubisch C; Schmidt G; Horvath J; Wappenschmidt B; Engel C; Arnold N; Dworniczak B; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
Breast Cancer Res; 2018 Jan; 20(1):7. PubMed ID: 29368626
[TBL] [Abstract][Full Text] [Related]
17. Primary fallopian tube carcinoma (PFTC) in a BRIP-1 mutation carrier: the first case report.
Grandi G; Caroli M; Alboni C; Cortesi L; Toss A; Barbieri E; Botticelli L; Facchinetti F
Fam Cancer; 2020 Oct; 19(4):291-295. PubMed ID: 32328861
[TBL] [Abstract][Full Text] [Related]
18. Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families.
Guénard F; Labrie Y; Ouellette G; Joly Beauparlant C; Simard J; ; Durocher F
J Hum Genet; 2008; 53(7):579. PubMed ID: 18414782
[TBL] [Abstract][Full Text] [Related]
19. Analysis of BRIP1 Variants among Korean Patients with BRCA1/2 Mutation-Negative High-Risk Breast Cancer.
Kim H; Cho DY; Choi DH; Jung GH; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Gil WH; Kim SW
Cancer Res Treat; 2016 Jul; 48(3):955-61. PubMed ID: 26790966
[TBL] [Abstract][Full Text] [Related]
20. Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?
Tomao F; Musacchio L; Di Mauro F; Boccia SM; Di Donato V; Giancotti A; Perniola G; Palaia I; Muzii L; Benedetti Panici P
Gynecol Oncol; 2019 Jul; 154(1):138-143. PubMed ID: 31079832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]